Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 451 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ritonavir (RTV) Clear all
Completed Phase 3 Interventional Results available

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

NCT00054717
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir, Ritonavir(r), Comparator Protease Inhibitor (CPI)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
96
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Sep 26, 2026, 12:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men

NCT00063804
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, AMD070
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 26, 2026, 12:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception

NCT01667978
View directory record Official record
Conditions
Pregnancy, HIV, AIDS
Interventions
Norethindrone acetate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Sep 26, 2026, 12:56 AM EDT
Completed Phase 2 Interventional Results available

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects

NCT00654147
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir & Lopinavir/ritonavir, Raltegravir and emtricitabine/tenofovir
Drug
Lead sponsor
Margaret A. Fischl, M.D.
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2015 · Synced Sep 26, 2026, 12:56 AM EDT
Recruiting Phase 1Phase 2 Interventional

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

NCT02140255
View directory record Official record
Conditions
HIV Infection
Interventions
Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r), Raltegravir (RAL), VRC01, Dolutegravir (DTG), VRC07-523LS
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 48 Hours
Enrollment
1,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
21
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 26, 2026, 12:56 AM EDT
Terminated Phase 2 Interventional Results available

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV

NCT00090779
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine/ tenofovir disoproxil fumarate, Lopinavir/Ritonavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
25
States / cities
San Diego, California • San Francisco, California • Torrance, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 26, 2026, 12:56 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

NCT00146328
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
86
States / cities
Phoenix, Arizona • Berkeley, California • Fountain Valley, California + 56 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Sep 26, 2026, 12:56 AM EDT
Completed Phase 2 Interventional

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

NCT01278134
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus placebo, RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
La Jolla, California • Sacramento, California • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 26, 2026, 12:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of Avanafil

NCT00770042
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Ritonavir, Ketoconazole, Erythomycin, Avanafil
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
21 Years to 45 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Sep 26, 2026, 12:56 AM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants

NCT00038480
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Days to 6 Months
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
14
States / cities
Oakland, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 26, 2026, 12:56 AM EDT
Completed Phase 1 Interventional

Antiretroviral Drug Interaction Study in Volunteers With HIV

NCT01479361
View directory record Official record
Conditions
HIV, PCP, Toxoplasmosis
Interventions
Atovaquone 750 mg twice daily, Atovaquone 1500 mg twice daily
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 26, 2026, 12:56 AM EDT
Completed Phase 1 Interventional

Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir

NCT00001133
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 26, 2026, 12:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers

NCT01519336
View directory record Official record
Conditions
Healthy Volunteer
Interventions
danoprevir, darunavir, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 26, 2026, 12:56 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

NCT00823979
View directory record Official record
Conditions
HIV-1
Interventions
UK-453,061 Dose 1, UK-453,061 Dose 2, Etravirine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
21
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Sep 26, 2026, 12:56 AM EDT
Not yet recruiting Phase 2 Interventional

SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction

NCT07597902
View directory record Official record
Conditions
Post-acute Sequelae of COVID-19, Long COVID
Interventions
Valacyclovir, Celecoxib, Paxlovid, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 26, 2026, 12:56 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors

NCT00543101
View directory record Official record
Conditions
HIV Infections
Interventions
Darunavir (DRV/r), continue on current dual boosted PI
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 26, 2026, 12:56 AM EDT
Recruiting Phase 1 Interventional

STARLITE for Unresectable High-Grade Gliomas

NCT06428045
View directory record Official record
Conditions
High Grade Glioma
Interventions
Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine, Ritonavir, Temozolomide, Focal Radiotherapy
Procedure · Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 26, 2026, 12:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

NCT00001119
View directory record Official record
Conditions
HIV Infections
Interventions
Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Hepatitis B Vaccine (Recombinant), Lamivudine, Zidovudine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
11
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Sep 26, 2026, 12:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Protease Inhibitors

NCT00774735
View directory record Official record
Conditions
Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions
GSK1349572
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2010 · Synced Sep 26, 2026, 12:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir

NCT00883935
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GSK1349572, Atazanavir 300 mg, Atazanavir 400 mg, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2009 · Synced Sep 26, 2026, 12:56 AM EDT
Completed Phase 1 Interventional Results available

A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.

NCT00435929
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, saquinavir [Invirase]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
5
States / cities
Chicago, Illinois • Somers Point, New Jersey • Voorhees Township, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 26, 2026, 12:56 AM EDT
Completed Not applicable Interventional

Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen

NCT00014937
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir, lamivudine/zidovudine, efavirenz, lamivudine, stavudine, zidovudine, didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
32
States / cities
Los Angeles, California • Denver, Colorado • Farmington, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2013 · Synced Sep 26, 2026, 12:56 AM EDT
Completed Phase 2 Interventional

An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.

NCT00081588
View directory record Official record
Conditions
HIV Infection
Interventions
TMC114
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
26
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 26, 2026, 12:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors

NCT00720590
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Atazanavir, Lopinavir/ritonavir, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Sep 26, 2026, 12:56 AM EDT